Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | HAT1 | O14929 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873354 | 0.92 | ALDH1A1 (0.52) | AKR1C3CNR1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2878276 | 0.92 | MAPT (0.48) | CNR1MAPTALDH1A1SMN1; SMN2ALOX5 | |
| SCHEMBL3998451 | 0.89 | ACLY (0.50) | ACLYAKR1C3CNR1MAPTALDH1A1 | |
| SCHEMBL2872278 | 0.87 | ACLY (0.51) | ACLYAKR1C3CNR1MAPTALDH1A1 | |
| SCHEMBL2873463 | 0.87 | ACLY (0.51) | ACLYAKR1C3CNR1MAPTALDH1A1 | |
| SCHEMBL2873564 | 0.86 | MAPT (0.44) | MAPTALDH1A1ALOX5POLBMGAM | |
| SCHEMBL2869092 | 0.85 | ALDH1A1 (0.54) | AKR1C3CNR1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2878337 | 0.85 | MAPT (0.47) | MAPTPOLBMGAM | |
| SCHEMBL3998593 | 0.80 | ALDH1A1 (0.50) | AKR1C3CNR1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2878392 | 0.80 | MGAM (0.45) | MAPTPOLBMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066628-B1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2066628-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008014186-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | ACLY 4136/4885AKR1C3 1702/4885CNR1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.